News

Company News

Targeted Delivery Excellence: Cosperpharma’s GalNAc Series for Liver-Specific Therapeutics20 2026-10

Targeted Delivery Excellence: Cosperpharma’s GalNAc Series for Liver-Specific Therapeutics

In the evolution of oligonucleotide therapeutics, achieving precise delivery to target tissues remains a paramount challenge. Cosperpharma is proud to introduce our specialized GalNAc (N-Acetylgalactosamine) series. As a high-affinity ligand for the asialoglycoprotein receptor (ASGPR), GalNAc enables the targeted delivery of conjugated siRNAs and antisense oligonucleotides directly to hepatocytes. Our comprehensive range of GalNAc derivatives provides researchers with the essential building blocks to enhance cellular uptake, improve therapeutic efficacy, and reduce off-target effects in liver-related diseases.
The Essential Toolkit: Cosperpharma’s Spacers and Phosphorylation Reagents20 2026-10

The Essential Toolkit: Cosperpharma’s Spacers and Phosphorylation Reagents

While the nucleobases form the core of an oligonucleotide, the success of complex synthetic designs often hinges on specialized linkers and terminal modifications. Cosperpharma is proud to present our comprehensive collection of "Other Phosphoramidites," featuring high-quality spacer monomers and chemical phosphorylation reagents. These essential building blocks empower researchers to introduce flexible gaps, modify terminal ends, and enhance the overall performance of their diagnostic probes and therapeutic oligonucleotides.
Conformational Lock, Biological Unlock: Cosperpharma’s 2'-FANA Phosphoramidites20 2026-10

Conformational Lock, Biological Unlock: Cosperpharma’s 2'-FANA Phosphoramidites

In the design of highly potent and stable oligonucleotide therapeutics, the ability to control the sugar conformation is a powerful tool. Cosperpharma is pleased to introduce our premium line of 2'-FANA (2'-Deoxy-2'-fluoro-arabinonucleic acid) Phosphoramidites. By combining the electron-withdrawing properties of fluorine with the unique structural geometry of arabinose, these monomers lock the sugar into a distinct C2'-endo conformation. This specialized chemistry is unlocking new possibilities for antisense oligonucleotides, siRNA, and advanced gene-editing applications.
Beyond the Ribose Ring: Cosperpharma’s PMO Phosphoramidites for Advanced Splice-Switching Therapeutics19 2026-10

Beyond the Ribose Ring: Cosperpharma’s PMO Phosphoramidites for Advanced Splice-Switching Therapeutics

As oligonucleotide therapeutics evolve, the need for backbones that offer superior stability and unique binding properties has led to the development of Morpholino chemistry. Cosperpharma is proud to introduce our high-purity PMO (Phosphorodiamidate Morpholino Oligomer) subunits. By replacing the ribose sugar with a six-membered morpholine ring and utilizing a neutral phosphorodiamidate backbone, these specialized building blocks enable the synthesis of oligomers with exceptional nuclease resistance and minimal off-target effects, making them ideal for advanced splice-switching and translation-blocking applications.
The Mirror-Image Advantage: Cosperpharma’s L-RNA Phosphoramidites19 2026-10

The Mirror-Image Advantage: Cosperpharma’s L-RNA Phosphoramidites

In the quest for ultimate biostability, nature's mirror image offers a remarkable solution. Cosperpharma is proud to introduce our specialized line of L-RNA Phosphoramidites. By utilizing the non-natural L-enantiomer of ribose, these monomers enable the synthesis of L-RNA (Spiegelmer) oligonucleotides. These mirror-image sequences are completely invisible to natural nucleases, offering unprecedented stability in biological systems. Our high-purity L-RNA building blocks are the key to developing long-lasting aptamers, therapeutics, and robust diagnostic tools.
Dual-Action Stabilization: Cosperpharma’s 2'-F-Reverse Phosphoramidites19 2026-10

Dual-Action Stabilization: Cosperpharma’s 2'-F-Reverse Phosphoramidites

Achieving maximum stability in therapeutic oligonucleotides often requires a multi-faceted chemical approach. Cosperpharma is excited to introduce our new line of 2'-F-Reverse Phosphoramidites. By combining the powerful nuclease resistance of 2'-Fluoro (2'-F) modification with the terminal protection capabilities of reverse (3'-DMT) orientation, these specialized monomers offer a dual-action strategy for designing highly stable antisense oligonucleotides, siRNAs, and aptamers.
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
RejectAccept